indium in-111 chloride (Indium In-111 Chloride) solution
[Mallinckrodt Inc.]
Rx Only.
Diagnostic - For use only in radiolabeling OncoScint® CR/OV (Satumomab Pendetide) and ProstaScintTM (Capromab Pendetide). Radioimmunotherapy - For use only in radiolabeling ZevalinTM (Ibritumomab Tiuxetan).
FOR SINGLE USE ONLY
Indium In 111 Chloride Sterile Solution is indicated for radiolabeling OncoScint CR/OV and ProstaScint preparations used for in vivo diagnostic imaging procedures. It is also indicated for radiolabeling ZevalinTM preparations used for Radioimmunotherapy procedures. It is supplied as a sterile, non-pyrogenic solution of Indium In 111 Chloride in 0.05 molar hydrochloric acid. No carrier has been added to the solution. Each 0.5 milliliter of the solution contains 185 megabequerels (5 millicuries) of indium In 111 chloride at time of calibration (specific activity of >1.85 GBq/μg Indium; >50 mCi/μg Indium at this time of calibration). The solution pH is 1.1 to 1.4.
Indium In 111 is cyclotron produced by the proton irradiation ((p, 2n) reaction) of cadmium Cd 112 enriched target. At time of calibration, it contains not less than 99.925% indium In 111 and, not more than 0.075% indium In 114m and zinc Zn 65 combined. At the time of expiration, it contains not less than 99.85% indium 111 and not more than 0.15% indium In 114m and zinc Zn 65 combined. No carrier has been added.
At the time of calibration, the Indium In 111 Chloride Sterile Solution contains not less than 95% of the Indium present as ionic In3+.
Indium In 111 Chloride Sterile Solution is tested for the following metallic impurities; copper, iron, cadmium, lead, zinc, nickel, and mercury, and contains extremely low levels of these metals. The sum of the individual impurity ratios for the metals listed is not more than 0.60 ppm.
Indium In 111 decays by electron capture to cadmium Cd 111 (stable) with a physical half-life of 67.32 hours (2.81 days)1. Photons useful for detection and imaging are listed in Table 1.
| Radiation | Mean Percent Per Disintegration | Mean Energy (keV) |
|
2Kocher, David C., "Radioactive Decay Data Tables", DOE/TIC-11026, 115 (1981). |
||
| Gamma-2 | 90.2 | 171.3 |
| Gamma-3 | 94.0 | 245.4 |
The exposure rate constant for 37 MBq (1 mCi) of Indium In 111 is 8.3 x 10-4 C/kg/hr (3.21 R/hr) at 1 cm. The specific gamma ray constant for Indium In 111 is 3.21 R/hr-mCi @ 1 cm1. The first half-value thickness of lead (Pb) is 0.023 cm. A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from interposition of various thicknesses of Pb is shown in Table 2. For example, the use of 0.834 cm of Pb will decrease the external radiation exposure by a factor of about 1000.
| Shield Thickness (Pb) cm | Coefficient of Attenuation |
| 0.023 | 0.5 |
| 0.203 | 10-1 |
| 0.513 | 10-2 |
| 0.834 | 10-3 |
| 1.12 | 10-4 |
These estimates of attenuation do not take into consideration the presence of longer-lived contaminants with higher energy photons, namely Indium In 114m.
To correct for physical decay of Indium In 111, the fractions that remain at selected intervals before and after calibration time are shown in Table 3.
|
*Calibration time |
|||
| Hours | Fraction Remaining | Hours | Fraction Remaining |
| -72 | 2.10 | 0* | 1.00 |
| -60 | 1.85 | 6 | 0.94 |
| -48 | 1.64 | 12 | 0.88 |
| -36 | 1.45 | 24 | 0.78 |
| -24 | 1.28 | 36 | 0.69 |
| -12 | 1.13 | 48 | 0.61 |
| -6 | 1.06 | 72 | 0.48 |
Please refer to the package insert for OncoScint CR/OV, ProstaScint or Zevalin for this information on the final drug product.
Indium In 111 Chloride Sterile Solution is indicated for radiolabeling OncoScint CR/OV or ProstaScmt preparations used for in vivo diagnostic imaging procedures. It is also indicated for radiolabeling Zevalin preparations used for Radioimmunotherapy procedures. Please refer to the package insert for OncoScint CR/OV, ProstaScint or Zevalin for information on the final drug product.
Please refer to the package insert for OncoScint CR/OV, ProstaScint, or Zevalin for this information on the final drug product.
CONTENTS OF THE VIAL OF INDIUM In 111 CHLORIDE SOLUTION ARE INTENDED ONLY TO BE USED AS AN INGREDIENT FOR RADIOLABELING ONCOSCINT CR/OV OR PROSTASCINT FOR USE IN IN VIVO DIAGNOSTIC IMAGING PROCEDURES OR TO BE USED AS AN INGREDIENT FOR RADIOLABELING ZEVALIN™ FOR USE IN RADIOIMMUNOTHERAPY PROCEDURES, AND ARE NOT TO BE ADMINISTERED DIRECTLY TO HUMANS.
Caution must be used to maintain proper aseptic technique while withdrawing and transferring contents of the Indium Chloride solution vial.
Do not use after expiration time and date indicated on vial label.
Contents of the vial are radioactive and adequate shielding and handling precautions must be maintained at all times.
Please refer to the package insert for OncoScint CR/OV, ProstaScint, or Zevalin for this information on the final drug product.
Please refer to the package insert for OncoScint CR/OV, ProstaScint, or Zevalin for this information on the final drug product.
Please refer to the package insert for OncoScint CR/OV, ProstaScint, or Zevalin for this information on the final drug product.
Please refer to the package insert for OncoScint CR/OV, ProstaScint, or Zevalin for this information on the final drug product.
Please refer to the package insert for OncoScint CR/OV, ProstaScint, or Zevalin for this information on the final drug product.
Please refer to the package insert for OncoScint CR/OV, ProstaScint, or Zevalin for this information on the final drug product.
Indium In 111 Chloride Sterile Solution is supplied in 10 mL vials containing 0.5 mL of solution. It is a sterile non-pyrogenic solution in 0.05 molar hydrochloric acid. No carrier is added to the solution. Each 0.5 mL contains 185 megabequerels (5 millicuries) of Indium In 111 Chloride at time of calibration. The pH of the solution is 1.1 to 1.4.
The contents of the vial are radioactive and adequate shielding and handling precautions must be maintained. Store at controlled room temperature 20-25°C (68-77°F) [See USP].
Storage and disposal of Indium In 111 Chloride Sterile Solution should be controlled in a manner that is in compliance with the appropriate regulations of the government agency authorized to license the use of the radionuclide.
The vial should be kept inside its transportation shield whenever possible and should be handled with forceps when contents are being removed.
OncoScint® CR/OV is a registered trademark of Cytogen Corporation. ProstaScint™ is a trademark of Cytogen Corporation. Zevalin™ is a trademark of IDEC Pharmaceuticals Corporation.
Revised 09/2002
Mallinckrodt Inc.
St. Louis, MO 63134
Professional Services: 1-800-325-3688
| Indium In-111 Chloride (Indium In-111 Chloride) | ||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||